Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Are CB2 Receptors a New Target for Schizophrenia Treatment?
Isadora Lopes Cortez, Naielly Rodrigues da Silva, Francisco Silveira Guimarães, et al.
Frontiers in Psychiatry (2020) Vol. 11
Open Access | Times Cited: 24

Showing 24 citing articles:

Consensus paper of the WFSBP task force on cannabis, cannabinoids and psychosis
Deepak Cyril D’Souza, Marta Di Forti, Suhas Ganesh, et al.
The World Journal of Biological Psychiatry (2022) Vol. 23, Iss. 10, pp. 719-742
Closed Access | Times Cited: 63
The role of microglia in neuropsychiatric disorders and suicide
Ralf Brisch, Szymon Wojtylak, Arthur Saniotis, et al.
European Archives of Psychiatry and Clinical Neuroscience (2021) Vol. 272, Iss. 6, pp. 929-945
Open Access | Times Cited: 53
Inflammation and Nitro-oxidative Stress as Drivers of Endocannabinoid System Aberrations in Mood Disorders and Schizophrenia
Gerwyn Morris, Luba Sominsky, Kenneth R. Walder, et al.
Molecular Neurobiology (2022) Vol. 59, Iss. 6, pp. 3485-3503
Closed Access | Times Cited: 30
Cannabis Pharmacogenomics: A Path to Personalized Medicine
Mariana Babayeva, Zvi G. Loewy
Current Issues in Molecular Biology (2023) Vol. 45, Iss. 4, pp. 3479-3514
Open Access | Times Cited: 16
Exploring causal mechanisms of psychosis risk
Dominic Oliver, Edward Chesney, Alexis E. Cullen, et al.
Neuroscience & Biobehavioral Reviews (2024) Vol. 162, pp. 105699-105699
Open Access | Times Cited: 7
The endocannabinoidome in neuropsychiatry: Opportunities and potential risks
Gerwyn Morris, Ken Walder, Stefan Kloiber, et al.
Pharmacological Research (2021) Vol. 170, pp. 105729-105729
Closed Access | Times Cited: 32
Molecular Alterations of the Endocannabinoid System in Psychiatric Disorders
Daniela Navarro, Ani Gasparyan, Francisco Navarrete, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 9, pp. 4764-4764
Open Access | Times Cited: 23
Cannabidiol (CBD) as a novel treatment in the early phases of psychosis
Edward Chesney, Dominic Oliver, Philip McGuire
Psychopharmacology (2021) Vol. 239, Iss. 5, pp. 1179-1190
Open Access | Times Cited: 32
Phytocannabinoids and schizophrenia: Focus on adolescence as a critical window of enhanced vulnerability and opportunity for treatment
Tibor Štark, Serena Di Martino, Filippo Drago, et al.
Pharmacological Research (2021) Vol. 174, pp. 105938-105938
Closed Access | Times Cited: 31
Lipid endocannabinoids in energy metabolism, stress and developmental programming
Mariana M. Almeida, Camilla P. Dias-Rocha, Camila Calviño, et al.
Molecular and Cellular Endocrinology (2021) Vol. 542, pp. 111522-111522
Closed Access | Times Cited: 23
The progress of small molecules against cannabinoid 2 receptor (CB2R)
Qinying Zhang, Ying Zhao, Jianan Wu, et al.
Bioorganic Chemistry (2024) Vol. 144, pp. 107075-107075
Closed Access | Times Cited: 3
Receptor-Dependent and Independent Regulation of Voltage-Gated Ca2+ Channels and Ca2+-Permeable Channels by Endocannabinoids in the Brain
Tomasz Boczek, Ludmiła Żylińska
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 15, pp. 8168-8168
Open Access | Times Cited: 20
Single nucleotide polymorphisms in the cannabinoid CB2 receptor: Molecular pharmacology and disease associations
Tahira Foyzun, M.J. Whiting, Kate K. Velasco, et al.
British Journal of Pharmacology (2024) Vol. 181, Iss. 15, pp. 2391-2412
Open Access | Times Cited: 2
Cannabinoid Type 2 Receptor Activation Reduces the Progression of Kidney Fibrosis Using a Mouse Model of Unilateral Ureteral Obstruction
Mallory L. Swanson, Kevin R. Regner, Bob Moore, et al.
Cannabis and Cannabinoid Research (2022) Vol. 7, Iss. 6, pp. 790-803
Closed Access | Times Cited: 11
Neuroimaging revealed long-lasting glucose metabolism changes to morphine withdrawal in rats pretreated with the cannabinoid agonist CP-55,940 during periadolescence
Nicolás Lamanna‐Rama, Karina S. MacDowell, Glenda M. Torres Lopez, et al.
European Neuropsychopharmacology (2023) Vol. 69, pp. 60-76
Open Access | Times Cited: 6
Endocannabinoid system alterations in schizophrenia: association with cannabis use and antipsychotic medication
Natalia Mansur Haddad, Leonardo Peroni De Jesus, Maurício H. Serpa, et al.
European Archives of Psychiatry and Clinical Neuroscience (2024)
Closed Access | Times Cited: 1
Target Discovery Using Deep Learning-Based Molecular Docking and Predicted Protein Structures With AlphaFold for Novel Antipsychotics
Yangsik Kim, Seyong Kim
Psychiatry Investigation (2023) Vol. 20, Iss. 6, pp. 504-514
Open Access | Times Cited: 3
Acceptability of cannabidiol in patients with psychosis
Edward Chesney, Doga Lamper, Millie Lloyd, et al.
Therapeutic Advances in Psychopharmacology (2022) Vol. 12, pp. 204512532211284-204512532211284
Open Access | Times Cited: 4
Investigation of Receptor-Ligand Interaction of Cannabidiol by Molecular Docking Method
Emre Fatih Ediz, Meltem Demirel Kars
Karadeniz Fen Bilimleri Dergisi (2023) Vol. 13, Iss. 2, pp. 398-414
Open Access | Times Cited: 2
Molecular Findings Guiding the Modulation of the Endocannabinoid System as a Potential Target to Treat Schizophrenia
Giuliana S. Zuccoli, Caroline Brandão‐Teles, Gabriela Maciel Vieira, et al.
Advances in experimental medicine and biology (2022), pp. 89-103
Closed Access | Times Cited: 3
Interactions of Catha edulis Forsk with CB2 receptors
Tuntufye Mwambyale, George Chirambo, Ibrahim Chikowe, et al.
Elsevier eBooks (2024), pp. 335-356
Closed Access
Análise do sistema endocanabinoide e ganho de peso em indivíduos com esquizofrenia em uso de clozapina
Natalia Mansur Haddad de Oliveira Santos
(2024)
Open Access
Cannabidiol reverses microglia activation and loss of parvalbumin interneurons and perineuronal nets in a mouse model of schizophrenia
Naielly Rodrigues da Silva, Davide Gobbo, Felipe V. Gomes, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access
Mecanismos celulares e neuroquímicos do efeito tipo-antipsicótico do canabidiol: envolvimento dos receptores 5-HT1A e CB2
Naielly Rodrigues da Silva
(2021)
Open Access
Page 1

Scroll to top